Accession Number : ADA288508
Title : Longterm Follow-up of Patients in CSP Number 298 , Treatment of Patients with 'Acquired Immune Deficiency Syndrome (AIDS) and AIDS related Complex'.
Descriptive Note : Final rept. 1 Apr 91-30 Apr 94,
Corporate Author : VETERANS ADMINISTRATION MEDICAL CENTER WASHINGTON DC
Personal Author(s) : Simberkoff, Michael S. ; Hartigan, Pamela M. ; Hamilton, John D.
PDF Url : ADA288508
Report Date : 01 OCT 1994
Pagination or Media Count : 25
Abstract : To evaluate the benefits of early (E) vs. Later (L) ZDV therapy, we enrolled 338 symptomatic HIV+ patients with CD4 counts of 200-500/cmm into a randomized, double-blind trial. Patients were assigned to initial ZDV 1,500 mg/day (E: 168 pts) or initial placebo (L. 170 The latter were switched to ZDV after progression to AIDS or to a court <200/cmm. All pts were offered ZDV 500 mg/day following completion of blinded follow-up. Blinded and final follow-up were completed in January 1991 and 1994, respectively. Median follow-up was 52 months. Progressions to AIDS occurred in 67 and 84 pts in the E and L therapy groups, respectively (rel. risk, 0.73; 95% CI, 0.52- l.01; p = 0.054). Death occurred in 74 and 73 pts in the E and L therapy groups, respectively (rel. risk, 0.99; 95% CI, 0.72-1.37; ns). We conclude that early compared with later ZDV provides marginal protection against progression to AIDS but no survival benefit.
Descriptors : *PATIENTS, *MEDICAL SERVICES, * PLACEBOS, *HUMAN IMMUNODEFICIENCY VIRUSES, RISK, CLINICAL MEDICINE, SIGNS AND SYMPTOMS, LONG RANGE(TIME), SURVIVAL(GENERAL), DEFICIENCIES, ILLNESS, INFECTIOUS DISEASES, DEATH, IMMUNITY, THERAPY*ACQUIRED IMMUNE DEFICIENCY SYNDROME, PUBLIC HEALTH.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE